| Autor: |
Cooksley, W. G. E., Piratvisuth, T., Lee, S.-D., Mahachai, V., Chao, Y.-C., Tanwandee, T., Chutaputti, A., Chang, W. Yu, Zahm, F. E., Pluck, N. |
| Předmět: |
|
| Zdroj: |
Journal of Viral Hepatitis; Jul2003, Vol. 10 Issue 4, p298-305, 8p |
| Abstrakt: |
Summary. Current therapies for chronic hepatitis B (CHB) have a number of limitations, and better treatment options are needed. Peginterferon α -2a (40 kDa) is superior to conventional interferon α -2a in the treatment of chronic hepatitis C. This is the first report on peginterferon α -2a (40 kDa) in the treatment of CHB. In this phase II study, 194 patients with CHB not previously treated with conventional interferon-α were randomized to receive weekly subcutaneous doses of peginterferon α -2a (40 kDa) 90, 180 or 270 μ g, or conventional interferon α -2a 4.5 MIU three times weekly. Twenty-four weeks of therapy were followed by 24 weeks of treatment-free follow-up. All subjects were assessed for loss of hepatitis B e antigen (HBeAg), presence of hepatitis B antibody (anti-HBe), suppression of hepatitis B virus (HBV) DNA, and normalization of serum alanine transaminase (ALT) after follow-up. At the end of follow-up, HBeAg was cleared in 37, 35 and 29% of patients receiving peginterferon α -2a (40 kDa) 90, 180 and 270 μ g, respectively, compared with 25% of patients on conventional interferon α -2a. The combined response (HBeAg loss, HBV DNA suppression, and ALT normalization) of all peginterferon α -2a (40 kDa) doses combined was twice that achieved with conventional interferon α -2a (24%vs 12%; P = 0.036). All treatment groups were similar with respect to frequency and severity of adverse events. These results indicate that peginterferon α -2a (40 kDa) is superior in efficacy to conventional interferon α -2a in chronic hepatitis B based on clearance of HBeAg, suppression of HBV DNA, and normalization of ALT. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
